Simeprevir's actual label says the drug is "indicated as a component of a combination antiviral treatment regimen." That is written broadly enough to where it's not clear that simeprevir+sofosbuvir use would necessarily be deemed off-label.
I certainly don't think it's going to be an issue in those advance stage patients, which are admittedly a much smaller part of the overall market. However, given the broad language in the label, it's possible insurers may well be more apt to reimburse the combo in less advanced patients, particularly given any rebates that JNJ may well be inclined to offer to participate in such combo sales.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.